BioNTech SE ( (BNTX) ) has provided an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, developed in collaboration with Pfizer. The settlement involves a payment of $791.5 million to the NIH, resolving past claims and adjusting future royalty arrangements. The settlement does not imply any admission of liability by BioNTech, and Pfizer has agreed to reimburse $364.5 million of the settlement amount.
More about BioNTech SE
BioNTech SE is a biotechnology company based in Mainz, Germany, primarily known for its development of mRNA-based vaccines and immunotherapies. The company is a significant player in the pharmaceutical industry, especially noted for its collaboration with Pfizer in producing the COVID-19 vaccine.
YTD Price Performance: 7.80%
Average Trading Volume: 820,259
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $27.28B
See more data about BNTX stock on TipRanks’ Stock Analysis page.
